NEW YORK (GenomeWeb News) — Protein translation company CODA Genomics today said it has expanded an ongoing collaboration with the Canadian antibody developer Viventia Biotech.
Under the terms of the agreement, CODA will apply its protein translational engineering systems to “various antibody projects within Viventia,” CODA said.
The Laguna Hills, Calif.-based company said its translational engineering platforms enable synthetic biology advances by “solving problems related to protein expression, activity and solubility.”
Financial terms of the agreement were not released.